{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:56:10Z","timestamp":1790668570214,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009946","name":"Allergopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4704"],"award-info":[{"award-number":["F4704"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P32470-B"],"award-info":[{"award-number":["P32470-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4701-B20"],"award-info":[{"award-number":["F4701-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4704-B20"],"award-info":[{"award-number":["F4704-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jaip.2022.03.007","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:13:17Z","timestamp":1648210397000},"page":"1999-2012.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User\u2019s Guide for Daily Clinical Practice"],"prefix":"10.1016","volume":"10","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Alvarez-Twose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Niedoszytko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.03.007_bib1","first-page":"3","article-title":"Mast cells and basophils","volume":"16","author":"Schwartz","year":"2002","journal-title":"Clin Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.03.007_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.03.007_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-immunol-071719-094903","article-title":"Mast cells in inflammation and disease: recent progress and ongoing concerns","volume":"38","author":"Galli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib6","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich\u2019s visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jaip.2022.03.007_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2022.03.007_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaip.2022.03.007_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib12","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib14","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaip.2022.03.007_bib15","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib16","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaip.2022.03.007_bib17","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib18","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.007_bib20","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.007_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jaip.2022.03.007_bib22","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaip.2022.03.007_bib23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib24","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7150\/thno.51872","article-title":"Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis","volume":"11","author":"Kluin-Nelemans","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jaip.2022.03.007_bib26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41375-019-0632-4","article-title":"Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry","volume":"34","author":"Kluin-Nelemans","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.007_bib27","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib28","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: Mutation-Adjusted Risk Score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2022.03.007_bib29","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study","volume":"8","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib30","article-title":"Mastocytosis: moving the field to precision and personalized medicine","volume":"38","author":"Castells","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.03.007_bib31","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.3390\/ijms20122976","article-title":"Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches","volume":"20","author":"Valent","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2022.03.007_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.anai.2021.07.025","article-title":"Mast cell disorders: a framework of allergy and hematology symptoms leading to personalized treatments","volume":"127","author":"Castells","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib33","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2021.068","article-title":"Systemic mastocytosis: multidisciplinary approach","volume":"13","author":"Zanotti","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jaip.2022.03.007_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib35","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jid.2020.12.030","article-title":"Clinical impact of skin lesions in mastocytosis: a multicenter study of the European Competence Network on Mastocytosis","volume":"141","author":"Aberer","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2022.03.007_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/modpathol.2013.117","article-title":"Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis","volume":"27","author":"Berezowska","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaip.2022.03.007_bib37","article-title":"Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin","volume":"9","author":"Fuchs","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib38","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib39","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.007_bib40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib41","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib45","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.3390\/ijms21239030","article-title":"Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine","volume":"21","author":"Valent","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2022.03.007_bib46","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Refined diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.jaip.2022.03.007_bib47","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41375-021-01406-y","article-title":"Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"36","author":"Zanotti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.007_bib48","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2022.03.007_bib49","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2022.03.007_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2005.01.011","article-title":"IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis","volume":"115","author":"Brockow","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/leu.2015.176","article-title":"Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression","volume":"30","author":"Mayado","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.007_bib52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.2018.212126","article-title":"Oncogenic D816V signaling in mast cells causes persistent IL-6 production","volume":"105","author":"Tobio","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2022.03.007_bib53","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24426","article-title":"Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","article-title":"Clinical and biologic diversity of leukemias occurring in patients with mastocytosis","volume":"37","author":"Sperr","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaip.2022.03.007_bib56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.molonc.2010.04.008","article-title":"High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V","volume":"4","author":"Fritsche-Polanz","year":"2010","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jaip.2022.03.007_bib57","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-018-0346-z","article-title":"KIT D816 mutated\/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis","volume":"33","author":"Jawhar","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.007_bib58","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1200\/JCO.2012.41.9549","article-title":"Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature","volume":"31","author":"Georgin-Lavialle","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2022.03.007_bib59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/modpathol.2012.199","article-title":"Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications","volume":"26","author":"Ryan","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaip.2022.03.007_bib60","doi-asserted-by":"crossref","first-page":"66299","DOI":"10.18632\/oncotarget.11812","article-title":"Mast cell sarcoma: new cases and literature review","volume":"7","author":"Monnier","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaip.2022.03.007_bib61","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","article-title":"Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities","volume":"133","author":"Lyons","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib62","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2022.03.007_bib63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10875-018-0506-y","article-title":"First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease","volume":"38","author":"Sabato","year":"2018","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib65","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib67","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0091-6749(89)90097-3","article-title":"A\u00a0double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis","volume":"83","author":"Kettelhut","year":"1989","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib68","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib69","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib70","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.03.007_bib71","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaip.2022.03.007_bib72","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2007.10.014","article-title":"Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy","volume":"121","author":"Bonadonna","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib73","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1398-9995.2009.02118.x","article-title":"Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy","volume":"64","author":"Niedoszytko","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib74","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2013.06.014","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations","volume":"1","author":"Bonadonna","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib75","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib76","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaip.2018.07.041","article-title":"Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis","volume":"7","author":"Constantine","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib77","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib78","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib79","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000504842","article-title":"Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA study)","volume":"236","author":"Distler","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2022.03.007_bib80","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaip.2017.11.025","article-title":"Anaphylactic reactions after discontinuation of Hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected","volume":"6","author":"Bonadonna","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib81","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2013.07.004","article-title":"Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome","volume":"1","author":"da Silva","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib82","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.iac.2014.01.012","article-title":"Treatment strategies in mastocytosis","volume":"34","author":"Siebenhaar","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.03.007_bib83","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/cea.12318","article-title":"Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders","volume":"44","author":"Valent","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib84","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5414\/ALX02196E","article-title":"Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis","volume":"5","author":"G\u00fclsen","year":"2021","journal-title":"Allergol Select"},{"key":"10.1016\/j.jaip.2022.03.007_bib85","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib86","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.exphem.2010.05.006","article-title":"In\u00a0vitro and in\u00a0vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V","volume":"38","author":"B\u00f6hm","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib87","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.03.007_bib88","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib89","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaip.2022.03.007_bib90","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.03.007_bib91","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.03.007_bib92","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib93","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.007_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib95","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2022.03.007_bib96","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"van der Veer","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.03.007_bib97","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ajh.24490","article-title":"Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study","volume":"91","author":"Broesby-Olsen","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib98","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaip.2022.03.007_bib99","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bone.2017.09.005","article-title":"Prevalence and risk factors for fragility fracture in systemic mastocytosis","volume":"105","author":"Degbo\u00e9","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.jaip.2022.03.007_bib100","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1016\/j.jaip.2021.08.001","article-title":"Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort","volume":"9","author":"Makovoz","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.007_bib101","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/rheumatology\/35.9.898","article-title":"Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B","volume":"35","author":"Lehmann","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaip.2022.03.007_bib102","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","article-title":"The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis","volume":"36","author":"Marshall","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaip.2022.03.007_bib103","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","article-title":"Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis","volume":"26","author":"Laroche","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaip.2022.03.007_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2014.06.015","article-title":"Zoledronic acid in osteoporosis secondary to mastocytosis","volume":"127","author":"Rossini","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2022.03.007_bib105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the treatment of mastocytosis-related osteoporosis: a case series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jaip.2022.03.007_bib106","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2022.03.007_bib107","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2022.03.007_bib108","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00277-017-3187-3","article-title":"KIT D816V\u2212 chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation","volume":"97","author":"Prats-Mart\u00edn","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaip.2022.03.007_bib109","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fonc.2020.00219","article-title":"Allogeneic hematopoietic stem cell transplantation in a rare case of tonsillar mast cell sarcoma","volume":"10","author":"Kubasch","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaip.2022.03.007_bib110","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.007_bib111","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2022.03.007_bib112","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaip.2022.03.007_bib113","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.007_bib114","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822002811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822002811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:53:09Z","timestamp":1778853189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":114,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2213219822002811"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.03.007","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User\u2019s Guide for Daily Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}